<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0001513'>Obesity</z:hpo> and a high-fat diet are associated with the risk and progression of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Low adiponectin levels may play an important role in the development of colon and other <z:hpo ids='HP_0001513'>obesity</z:hpo>-related <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>No previous studies have directly investigated the mechanistic effects of adiponectin on <z:hpo ids='HP_0003003'>colon cancer</z:hpo> in the settings of <z:hpo ids='HP_0001513'>obesity</z:hpo>, a high-fat diet and/or adiponectin deficiency </plain></SENT>
<SENT sid="3" pm="."><plain>OBJECTIVE: To investigate the effects of adiponectin on the growth of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in adiponectin-deficient or <z:mp ids='MP_0002169'>wild-type</z:mp>-C57BL/6 mice fed a low-fat or high-fat diet </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Mice fed a high-fat-diet gained more weight and had larger <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> than mice fed a low-fat-diet </plain></SENT>
<SENT sid="5" pm="."><plain>Adiponectin administration suppressed implanted <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumour growth</z:e>, causing larger central necrotic areas </plain></SENT>
<SENT sid="6" pm="."><plain>Adiponectin treatment also suppressed <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> assessed by CD31 staining and VEGFb and VEGFd <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> obtained from mice fed a high-fat-diet and from adiponectin-deficient mice </plain></SENT>
<SENT sid="7" pm="."><plain>Adiponectin treatment decreased serum insulin levels in mice on a high-fat-diet and increased serum-interleukin (IL)-12 levels in adiponectin-deficient mice </plain></SENT>
<SENT sid="8" pm="."><plain>In vitro, it was found that adiponectin directly controls malignant potential (cell proliferation, <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, invasion and colony formation) and regulates metabolic (AMPK/S6), inflammatory (STAT3/VEGF) and cell cycle (p21/p27/p53/cyclins) signalling pathways in both mouse MCA38 and human HT29, HCT116 and LoVo <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell lines in a LKB1-dependent way </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: These new mechanistic and pathophysiology studies provide evidence for an important role of adiponectin in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>The data indicate that adiponectin or analogues might be useful agents in the management or chemoprevention of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
</text></document>